Protease-sparing regimen in a real-life practice with naïve patients: an equal opportunity approach?

abstract：PURPOSE:Previous studies with intermittent interleukin-2 (IL-2) therapy using intermediate and high levels of IL-2 have demonstrated significant increases in the CD4 + T cell count in HIV-infected patients. Intermittent regimens are amenable to outpatient use, but severe adverse events are frequently experienced with i...

journal_title：HIV clinical trials

authors： Lalezari JP,Beal JA,Ruane PJ,Cohen CJ,Jacobson EL,Sundin D,Leong WP,Raffanti SP,Wheeler DA,Anderson RD,Keiser P,Schrader SR,Goodgame JC,Steinhart CR,Murphy RL,Wolin MJ,Smith KA

更新日期：2000-11-01 00:00:00

abstract：BACKGROUND:Raltegravir (RAL) constitutes the first available integrase strand transfer inhibitor (INSTI) available in clinical practice. Three independent pathways have been described to confer resistance to RAL. Secondary mutations with little effect on INSTI susceptibility and additional substitutions with an uncerta...

journal_title：HIV clinical trials

authors： Gutiérrez C,Hernández-Novoa B,Pérez-Elías MJ,Moreno AM,Holguín A,Dronda F,Casado JL,Moreno S

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:A safe, effective, easy-to-dose antiretroviral therapy that minimizes hepatic complication risk is essential in optimizing HIV-HCV treatment. Nucleoside-sparing boosted protease inhibitor monotherapy may achieve this goal. METHODS:A prospective, open-label pilot simplification study of once-daily lopinavir/...

journal_title：HIV clinical trials

authors： Cooper C,la Porte C,Tossonian H,Sampalis J,Ackad N,Conway B

更新日期：2012-07-01 00:00:00

abstract：BACKGROUND:In recent ritonavir-boosted protease inhibitor (PI) studies, high efficacy rates have been observed, with few PI mutations detected. METHOD:To better understand the types of mutations observed and their phenotypic impact and the likelihood of virologic failure (VF) on a regimen that includes either a ritona...

journal_title：HIV clinical trials

authors： Ross L,Vavro C,Wine B,Liao Q

更新日期：2006-11-01 00:00:00

abstract：PURPOSE:To characterize the steady-state pharmacokinetic combination of the nonpeptidic protease inhibitor tipranavir (TPV) with ritonavir (RTV) in 95 healthy adult volunteers, a phase 1, single-center, open-label, randomized, parallel-group trial was conducted. METHOD:Participants received 250-mg self-emulsifying dru...

journal_title：HIV clinical trials

authors： MacGregor TR,Sabo JP,Norris SH,Johnson P,Galitz L,McCallister S

更新日期：2004-11-01 00:00:00

abstract：OBJECTIVES:Statins are lipid-lowering drugs that exhibit anti-Inflammatory and immune-modulatory properties, leading to a reduction of serum levels of C-reactive protein (CRP) in the general population. DESIGN:To assess the anti-inflammatory effects of statins in HIV-infected patients, because very limited data are av...

journal_title：HIV clinical trials

authors： Calza L,Vanino E,Salvadori C,Manfredi R,Colangeli V,Cascavilla A,Di Bari MA,Motta R,Viale P

更新日期：2014-01-01 00:00:00

abstract：PURPOSE:To assess the virologic and immunologic response to a boosted double-protease inhibitor (PI) regimen of highly pretreated patients infected with HIV-1 and to examine the role of PI resistance and concentration of serum saquinavir. METHOD:In an open-label prospective study, lopinavir/ritonavir, saquinavir-sgc, ...

journal_title：HIV clinical trials

authors： Smith GH,Boulassel MR,Klien M,Gilmore N,MacLeod J,LeBlanc R,René P,Routy JP,Lalonde RG

更新日期：2005-03-01 00:00:00

abstract：BACKGROUND:To improve the dosing frequency and pill burden of antiretroviral therapy, we compared two once-daily dosed regimens to a twice-daily dosed regimen. METHOD:HIV-1-infected, antiretroviral drug-naïve adults were randomized to either twice-daily nelfinavir and stavudine and once-daily didanosine (regimen A) or...

journal_title：HIV clinical trials

authors： Lowe SH,Wensing AM,Hassink EA,ten Kate RW,Richter C,Schreij G,Koopmans PP,Juttmann JR,van der Tweel I,Lange JM,Borleffs JC

更新日期：2005-09-01 00:00:00

abstract：PURPOSE:This retrospective study investigates the effect of prior nucleoside (nucleoside reverse transcriptase inhibitor [NRTI]) experience on 2-year virologic response to an initial protease inhibitor-highly active antiretroviral therapy (PI-HAART) regimen. METHOD:152 patients who started a PI (excluding saquinavir h...

journal_title：HIV clinical trials

authors： Kazanjian P,Tashima K,Hollander T,Kaul D

更新日期：2001-05-01 00:00:00

abstract：OBJECTIVES:Antiretroviral regimen switching may be considered for HIV-1-infected, virologically-suppressed patients to enable treatment simplification or improve tolerability, but should be guided by knowledge of pre-existing drug resistance. The current study examined the impact of pre-existing drug resistance mutatio...

journal_title：HIV clinical trials

authors： Porter DP,Toma J,Tan Y,Solberg O,Cai S,Kulkarni R,Andreatta K,Lie Y,Chuck SK,Palella F,Miller MD,White KL

更新日期：2016-02-01 00:00:00

abstract：PURPOSE:The objective was to evaluate the impact of an intervention for improving adherence to antiretroviral therapies (HAART) in HIV-infected patients. METHOD:We designed a prospective, controlled, randomized trial to assess the impact of an educational and counseling intervention in addition to standard of care. At...

journal_title：HIV clinical trials

authors： Pradier C,Bentz L,Spire B,Tourette-Turgis C,Morin M,Souville M,Rebillon M,Fuzibet JG,Pesce A,Dellamonica P,Moatti JP

更新日期：2003-03-01 00:00:00

abstract：PURPOSE:Treatment options for HIV-associated lipodystrophy syndrome (HALS) remain limited. The objective of this randomized open-label study was to compare three emerging therapies, rosiglitazone, pravastatin, and growth hormone alone and together, in men and women with HALS. METHOD:Sixty-four subjects received daily ...

journal_title：HIV clinical trials

authors： Macallan DC,Baldwin C,Mandalia S,Pandol-Kaljevic V,Higgins N,Grundy A,Moyle GJ

更新日期：2008-07-01 00:00:00

abstract：BACKGROUND:The best method for assessment of functional status in human immunodeficiency virus type 1 (HIV-1) infected persons is unknown. OBJECTIVE:We hypothesized that 3 instruments to assess frailty or disability in elderly populations would perform similarly in HIV-1-infected persons. METHODS:HIV-infected subject...

journal_title：HIV clinical trials

authors： Erlandson KM,Allshouse AA,Jankowski CM,Duong S,Mawhinney S,Kohrt WM,Campbell TB

更新日期：2012-11-01 00:00:00

abstract：:Tuberculosis and HIV have combined to present a major threat to global public health. Each disease has a negative effect on the other, and mortality in patients with both tuberculosis and HIV is higher than that caused by either condition alone. In regions such as sub-Saharan Africa, as many as a third or more of all ...

journal_title：HIV clinical trials

authors： Schluger NW,Burzynski J

更新日期：2001-07-01 00:00:00

abstract：PURPOSE:Selecting the optimal treatment regimen for antiviral-naive patients may be difficult, given the concern about the antiviral activity, the development of drug resistance, and the increase in drug costs. This study evaluates the costs and effectiveness of using lopinavir/ritonavir (LPV/r) vs. nelfinavir (NFV), b...

journal_title：HIV clinical trials

authors： Simpson KN,Luo MP,Chumney E,Sun E,Brun S,Ashraf T

更新日期：2004-09-01 00:00:00

abstract：PURPOSE:The purpose of this study was to evaluate the short-term effects (up to 6 months) of tenofovir disoproxil fumarate (DF) use on renal function in patients being treated for HIV-1 infection. METHOD:The charts of 447 HIV-1-infected patients who received at least three months of tenofovir DF treatment were reviewe...

journal_title：HIV clinical trials

authors： Scott JD,Wolfe PR,Bolan RK,Guyer B

更新日期：2006-03-01 00:00:00

abstract：METHOD:Analysis of virological, immunological, and clinical data over 24 weeks of treatment of drug-experienced patients administered didanosine (ddI) and tenofovir (TDF) plus either PI or NNRTI (17 patients) compared to 14 patients on ddI plus lamivudine and to 19 patients on ddI plus stavudine. RESULTS:Patients trea...

journal_title：HIV clinical trials

authors： Di Biagio A,Beltrame A,Cenderello G,Ferrea G,De Maria A

更新日期：2006-01-01 00:00:00

abstract：PURPOSE:We investigated the evolution of serum lipid levels in HIV-infected pregnant women and the potential effect of antiretroviral treatment during pregnancy using data from a national surveillance study. METHOD:Fasting lipid measurements collected during routine care in pregnancy were used, analyzing longitudinal ...

journal_title：HIV clinical trials

authors： Floridia M,Tamburrini E,Ravizza M,Tibaldi C,Ravagni Probizer MF,Anzidei G,Sansone M,Mori F,Rubino E,Meli M,Dalzero S,Guaraldi G,Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy.

更新日期：2006-07-01 00:00:00

abstract：BACKGROUND:Unannounced home-based pill counts conducted in person or on the telephone are reliable and valid for monitoring medication adherence. However, expecting to have one's pills counted, organizing medications for pill counts, and increased attention from the person conducting the pill counts may have reactive e...

journal_title：HIV clinical trials

authors： Kalichman SC,Amaral C,Swetsze C,Eaton L,Kalichman MO,Cherry C,Detorio M,Caliendo AM,Schinazi RF

更新日期：2010-11-01 00:00:00

abstract：OBJECTIVE:To evaluate the safety profile and efficacy of salvage regimens containing amprenavir (APV) 600 mg twice daily and ritonavir (RTV) 200 mg twice daily. DESIGN:Prospective, single-center study. METHOD:The patient database of the department of infectious diseases was screened for patients who had failed at lea...

journal_title：HIV clinical trials

authors： Arvieux C,Tattevin P,Souala FM,Jaccard P,Ruffault A,Bentué-Ferrer D,Tribut O,Chapplain JM,Dupont M,Bouvier C,Michelet C

更新日期：2002-03-01 00:00:00

abstract：PURPOSE:To investigate the factors that contribute to willingness to participate in HIV clinical trials and to determine the impact of a brief intervention on willingness to participate. METHODS:115 consecutive outpatients receiving HIV primary care participated in this prospective study. Each patient completed a ques...

journal_title：HIV clinical trials

authors： Volkmann ER,Claiborne D,Currier JS

更新日期：2009-03-01 00:00:00

abstract：BACKGROUND:Perinatally acquired HIV-infected (PaHIV) young adults undergo neurodevelopment in the presence of HIV infection and antiretroviral therapy, which may lead to neurocognitive (NC) impairment. Knowledge of NC function in this group is sparse and control data lacking. We compared cerebral function in young adul...

journal_title：HIV clinical trials

authors： Ashby J,Foster C,Garvey L,Wan T,Allsop J,Paramesparan Y,Taylor-Robinson SD,Fidler S,Winston A

更新日期：2015-03-01 00:00:00

abstract：:When prescribed appropriately and taken adherently, antiretroviral therapy can consistently and durably suppress HIV replication, potentially translating into years of near normal health for HIV-infected persons. However, presently available antiretrovirals are associated with a cluster of physical and metabolic sympt...

journal_title：HIV clinical trials

authors： Kravcik S

更新日期：2004-05-01 00:00:00

abstract：BACKGROUND:Immune response rates following influenza vaccination are often lower in HIV-infected individuals. Low vitamin D levels were correlated with weak immune response in cancer patients and are known to be lower in HIV-infected patients. METHODS:Diagnostic study to determine immune response against the H1N1v com...

journal_title：HIV clinical trials

authors： Bickel M,Lassmann C,Wieters I,Doerr HW,Herrmann E,Wicker S,Brodt HR,Stephan C,Allwinn R,Jung O

更新日期：2013-07-01 00:00:00

abstract：:This article reports noteworthy HIV/AIDS clinical trials presented at the XVth International AIDS Conference, Bangkok, July 2004, and also outlines goals of comprehensive prevention, care, treatment, and monitoring plans. The Bangkok conference theme was "Access for All." Outlined are goals of comprehensive prevention...

journal_title：HIV clinical trials

authors： Idemyor V

更新日期：2005-01-01 00:00:00

abstract：OBJECTIVES:Despite substantial improvements in HIV outcomes with combination antiretroviral therapy (cART), morbidity and mortality remain above population norms. The gut mucosal immune system is not completely restored by cART, and the resultant microbial translocation may contribute to chronic inflammation, inadequat...

journal_title：HIV clinical trials

authors： Kim CJ,Walmsley SL,Raboud JM,Kovacs C,Coburn B,Rousseau R,Reinhard R,Rosenes R,Kaul R

更新日期：2016-07-01 00:00:00

abstract：PURPOSE:To prospectively determine incidence, prevalence, and extent of lipodystrophy (LD) and associated metabolic changes. METHOD:This was a prospective cohort study. Body habitus changes were determined by anthropometrics, photography, and regional dual-energy X-ray absorptiometry (DXA) scan. Metabolic parameters i...

journal_title：HIV clinical trials

authors： Walmsley S,Cheung AM,Fantus G,Gough K,Smaill F,Azad,Diong C,Raboud J

更新日期：2008-09-01 00:00:00

abstract：BACKGROUND:We hypothesized that nitazoxanide (NTZ) added to pegylated interferon alfa-2a (PEG-IFN) and weight-based ribavirin (WBR) would improve hepatitis C virus (HCV) virologic responses in HCV treatment-naïve HIV-1/HCV genotype 1 coinfected persons. METHODS:Prospective, single-arm study in which subjects received ...

journal_title：HIV clinical trials

authors： Amorosa VK,Luetkemeyer A,Kang M,Johnson VA,Umbleja T,Haas DW,Yesmin S,Bardin MC,Chung RT,Alston-Smith B,Tebas P,Peters MG

更新日期：2013-11-01 00:00:00

abstract：OBJECTIVE:The efficacy of Product R, a nontoxic peptide-nucleic acid, was tested in 43 HIV-infected adults naïve to antiretroviral therapy. METHOD:Patients were randomized to receive Product R (21 patients) or placebo (22 patients). Dosage was two 1 mL subcutaneous injections daily on days 1-14, followed by 1 mL daily...

journal_title：HIV clinical trials

authors： Levett PN,Hirschman SZ,Roach TC,Broome H,Alexander RJ,Fraser HS

更新日期：2002-07-01 00:00:00

abstract：OBJECTIVES:Week 96 efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) was compared to efavirenz (EFV) in subset of 1,096 subjects who received emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in pooled data from 2 phase 3 studies. METHODS:ECHO and THRIVE are double...

journal_title：HIV clinical trials

authors： Nelson MR,Elion RA,Cohen CJ,Mills A,Hodder SL,Segal-Maurer S,Bloch M,Garner W,Guyer B,Williams S,Chuck S,Vanveggel S,Deckx H,Stevens M

更新日期：2013-05-01 00:00:00